Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilunermin alfa
- Development stage
- Phase 1
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intracavitary, Intraperitoneal, Intrapleural, Intravesical
01
Overview
Rilunermin alfa (formerly known as SCB-313) is a fully human recombinant fusion protein developed by Clover Biopharmaceuticals. It is engineered using the Trimer-Tag technology platform and consists of a trimeric form of the TNF-related apoptosis-inducing ligand (TRAIL). The drug targets the extrinsic apoptosis pathway by binding to death receptors DR4 and DR5, leading to physiologic trimerization and potent activation of apoptosis in tumor cells. Rilunermin alfa is being developed primarily for the treatment of intracavitary malignancies such as malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis[1][2][4][6].
- Other names
- recombinant human TRAIL-Trimer fusion proteinApo2LApo-2LApo 2L
02
Targets
TNFRSF10B (DR5)TNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on rilunermin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilunermin alfa.